Functional Concept
In an unusual move, Lilly seeks pitches from US states for slice of $27B buildout
Eli Lilly, Investments, United States, Lilly ‘s
Ajax Health and KKR Form New Heart Failure Treatment Platform with Boston Scientific Technology
Ajax Health, KKR, Boston Scientific, FlowMod, heart failure treatment, medical device platform
DOGE terminates leases for 30 FDA sites across 23 states
DOGE, United States Food and Drug Administration, Site, United States Food and Drug Administration, Clinical action, Government, leases
FDA Pauses BioNTech’s Malaria Vaccine Trial Amid Regulatory Scrutiny
BioNTech, malaria vaccine, FDA clinical hold, RNA vaccine, regulatory challenges
Atara Biotherapeutics Halves Workforce Amid FDA Setbacks for Key Therapies
Atara Biotherapeutics, layoffs, FDA clinical hold, Ebvallo, ATA3219, manufacturing issues
AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal
Eisai Cuts 121 US Jobs in Strategic Restructuring
Eisai, layoffs, restructuring, US operations, pharmaceutical industry, Leqembi, Alzheimer’s disease
Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial
Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop
Eikon pulls in $351M as lead drugs begins Phase III journey
Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase